693245-80-6

Usage

Uses

Used in Research Applications:
2H-Pyran-3(4H)-one,dihydro-4,4-dimethoxy-(9CI) is used as a research compound for studying its chemical properties and potential interactions with other molecules, which can contribute to the development of new materials or pharmaceuticals.
Used in Pharmaceutical Industry:
2H-Pyran-3(4H)-one,dihydro-4,4-dimethoxy-(9CI) is used as a starting material or intermediate in the synthesis of pharmaceutical compounds, potentially leading to the discovery of new drugs with therapeutic applications.
Used in Industrial Applications:
2H-Pyran-3(4H)-one,dihydro-4,4-dimethoxy-(9CI) is used as a chemical intermediate in the production of various industrial products, such as specialty chemicals, dyes, or coatings, where its unique structure may provide specific benefits or properties.

Upstream product

• 104681-92-7 4,4-dimethoxytetrahydro-2H-pyran-3-ol 
• 4732-69-8 Chloro-oxo-acetic acid 
• 17327-22-9 4-methoxy-2,6-dihydropyran 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 

Downstream Products

• 1240390-32-2 2-amino-1,5-anhydro-2,4-dideoxy-L-threo-pentitol 
• 1268516-32-0 benzyl ((3S)-4-oxotetrahydro-2H-pyran-3-yl)carbamate 
• 1268516-33-1 benzyl ((3S,4S)-4-hydroxytetrahydro-2H-pyran-3-yl)carbamate 
• 1268515-64-5 (3S)-3-(benzylyoxy)-4,4-dimethoxytetrahydro-2H-pyran 
• 1268515-65-6 (3S)-3-(benzyloxy)-tetrahydro-4H-pyran-4-one 
• 1268515-66-7 (3R,4S)-3-(benzyloxy)tetrahydro-2H-pyran-4-amine 
• 1096770-58-9 (3R,4S)-4-aminotetrahydro-2H-pyran-3-ol 
• 131067-76-0 3-methyl-tetrahydro-pyran-4-one 
• 851916-41-1 (R)-3-methoxydihydro-2H-pyran-4(3H)-one 

Relevant academic research and scientific papers

DIAZA-BENZOFLUORANTHRENE COMPOUNDS

Disclosed are a series of diaza-benzofluoranthrene compounds. The present invention particularly relates to a compound represented by formula (I), pharmaceutically acceptable salts or tautomers thereof.

BENZOISOQUINOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to substituted benzoisoquinolinone compounds, their salts, pharmaceutical compositions comprising them and their use in therapy. In particular, the invention is directed substituted benzoisoquinolinone compounds which are muscarinic M1 receptor positive allosteric modulators. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M1 receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M1 receptors are involved.

QUINAZOLINE COMPOUNDS USEFUL AS M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to compounds of Formula (I): (Formula (I)) and pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R7, R8, R9, R11, n and p are defined herein. The compounds of Formula (I) are M1 receptor positive allosteric modulators that are useful in the treatment of diseases in which the M1 receptor is involved, including Alzheimer's disease, schizophrenia, pain and sleep disorders. The invention also relates to pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier, and to methods of using the compounds of Formula (I) in the treatment of diseases mediated by the M1 receptor.

FUSED CYCLOPENTYL ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). wherein: R0, R1, R2, R3, R4, R5, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I)

DIHYDROBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to dihydrobenzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease

N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to N-linked lactam compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

TETRAHYDROQUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to tetrahydroquinoline amide compounds of formula (I) (Formula should be inserted here) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to heterocyclic fused phenanthrolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to aminobenzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimers disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor

PYRIDOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.